Lupus Research Alliance News
Thank you 2019 Half-Marathon Team Life Without Lupus!

Thanks to the Lupus Research Alliance Team Life Without Lupus, with runners who pounded the pavements at the United Airlines NYC Half Marathon on Sunday to raise funds for lupus research. Every one of those 13.1 miles bring us closer in the journey to Life Without Lupus – their invaluable steps brought the Team’s fundraising […] READ MORE

Peripheral Nervous System Involvement in Systemic Lupus Erythematosus: A Retrospective Study on Prevalence, Associated Factors and Outcome

A new study published in the peer-reviewed journal Lupus shows that lupus can cause damage to the peripheral nervous system (nerves throughout the body outside of the brain and spinal cord). Researchers from several hospitals in Italy analyzed medical records of 1224 lupus patients. Involvement of the peripheral nervous system was seen in 6.9% of […] READ MORE

Lupus Research Alliance and National Minority Quality Forum Release Recommendations to Advance New Lupus Treatments by Increasing Diversity in Clinical Trial Participation

NEW YORK, NY. March 14, 2019.  The Lupus Research Alliance (LRA) and the National Minority Quality Forum (NMQF) today released the insightful report, Addressing the Challenges of Clinical Research Participation Among Populations Disproportionately Impacted by Lupus. The report presents findings and actionable recommendations ranging in scope that can be implemented by any individual or group seeking […] READ MORE

Frailty Measure Predicts Mortality Risk Among People with Lupus

March 11, 2019 A new study published in Arthritis & Rheumatology by many top lupus clinicians found that a frailty index (FI) provides a novel measure of health among people with lupus.  Constructed using data from the Systemic Lupus International Collaborating Clinics (SLICC) group, the FI also predicts risk of mortality. The Systemic Lupus Erythematosus […] READ MORE

Lupus Therapeutics Partners with Takeda to Test Potential Treatment for Lupus

New York, NY– March 1.  The Lupus Research Alliance and its affiliate, Lupus Therapeutics announced a collaboration with Takeda Pharmaceutical Company Limited, to evaluate the investigational biologic TAK-079 as a potential new therapy for lupus in a Phase 1 trial (NCT03724916).  The national study will be conducted in 20 research centers throughout the country, many […] READ MORE

Lupus Research Alliance Congratulates NIH on 5-Year AMP Success

February 28, 2019 NEW YORK, NY. As a co-sponsor of the National Institutes of Health (NIH) public-private Accelerating Medicines Partnership (AMP), the Lupus Research Alliance is proud to share the project’s five-year achievements reported in Nature Reviews Drug Discovery.  In the article, NIH Director Dr. Francis Collins points to new technology standards AMP created for […] READ MORE

Positive Early Results for BIIB059 as New Treatment Strategy

February 28, 2019 Proteins of the immune system, known as type I interferons, are responsible in part for manifestations of lupus. For this reason, type I interferons are a very attractive target for lupus drug development. In 2015, excitement surrounded the release of positive phase II data with anifrolumab, a therapeutic antibody that blocks type […] READ MORE

LRA-funded Research Backs New Lupus Nephritis Clinical Trial

February 28, 2019 The biotechnology company Equillium Inc. just announced plans for a Phase 1 study to test the investigational monoclonal antibody EQ001 as a potential treatment for lupus nephritis (LN) that has not responded to existing treatment. The basis for this study is in part due to work conducted by Dr. Chandra Mohan that […] READ MORE

Learn and connect with our community!